Syn 1002
Alternative Names: PAT; Peptide analogue of thymulin; SYN 1002; Syn1002Latest Information Update: 02 Oct 2021
At a glance
- Originator INSERM
- Developer CLL PHARMA
- Class Analgesics; Anti-inflammatories; Antirheumatics; Oligopeptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Neuropathic pain; Pain; Rheumatoid arthritis
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Crohn's-disease in France
- 28 May 2018 No recent reports of development identified for phase-I development in Pain in France
- 31 May 2016 Phase-I development is ongoing for Pain and Crohn's disease in France (CII PHARMA pipeline, May 2016)